Identifying Genomic Drivers of Prostate Cancer Progression and Drug Resistance in Tumors and Circulating DNA
Abstract
The landscape of genomic alterations in early and advanced prostate cancer has been well established. However, the association of genomic changes with disease progression and clinical outcomes and their application to clinical decision-making remain unclear. In my initial application, I proposed to leverage evolving large genomic datasets to identify genomic drivers of prostate cancer progression and drug resistance. Since the start of the project, I have accomplished the major goals outlined in the application: I led the publication of a large multi-institutional study correlating advanced prostate cancer genomics with clinical outcomes (the SU2C-PCF dataset) and published several large studies including the characterization of microsatellite instability-high prostate cancer, CDK12mutations across solid tumors, DNA repair alterations and responses to PARP inhibition and platinum chemotherapy, genomic associations with outcomes in newly diagnosed metastatic prostate cancer, and racial genomic disparities.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2022
- Accession Number
- AD1191223
Entities
People
- Wassim Abida
Organizations
- Memorial Sloan Kettering Cancer Center